www.feizichem.com    Shijiazhuang FeiZi Chemical Technology Co., Ltd

May 29, 2025 – Leading domestic pharmaceutical company Qilu Pharmaceutical Co., Ltd. conducted a specialized on-site audit at Shijiazhuang Feizi Chemical Technology Co., Ltd., focusing on the production process and quality management of the pharmaceutical intermediate, benzyltributylammonium chloride.

Audit Focus and Significance
Benzyltributylammonium chloride, as a critical intermediate in pharmaceuticals, directly impacts the quality of the final drug products due to its purity and stability. The audit team systematically reviewed Feizi Chemical's production equipment, production processes, testing records, and environmental controls, with particular attention to the suitability verification of this compound as an active pharmaceutical ingredient (API) in formulations. This audit marked a comprehensive quality assessment of Feizi Chemical by a top-tier pharmaceutical company.

Mutual Empowerment Drives Industry Advancement
Leveraging its extensive experience in passing international certifications, Qilu provided Feizi Chemical with recommendations for optimizing production processes. In turn, Feizi Chemical demonstrated its technical expertise in the field of pharmaceutical intermediates. Both parties expressed their commitment to establishing a long-term collaboration mechanism for raw material technical standards, aligning with the recent regulations from the National Medical Products Administration (NMPA) on traceability management in pharmaceutical production chains.

We highly recommend the following products:

Benzyltributylammonium chloride    CAS:   23616-79-7
2,4-Diamino-6-hydroxypyrimidine    CAS:   56-06-4